203 related articles for article (PubMed ID: 28945826)
1. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Bernichon E; Vallard A; Wang Q; Attignon V; Pissaloux D; Bachelot T; Heudel PE; Ray-Coquard I; Bonnet E; de la Fouchardière A; Faure C; Chopin N; Beurrier F; Racadot S; Sunyach MP; Rancoule C; Perol D; Corset V; Agrapart V; Tinquaut F; Blay JY; Magné N; Trédan O
Ann Oncol; 2017 Nov; 28(11):2773-2779. PubMed ID: 28945826
[TBL] [Abstract][Full Text] [Related]
2. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
3. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
[TBL] [Abstract][Full Text] [Related]
4. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
5. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
Zhou Y; Simmons J; Jordan CD; Sonbol MB; Maihle N; Tang SC
Clin Breast Cancer; 2019 Oct; 19(5):354-362.e7. PubMed ID: 31262687
[TBL] [Abstract][Full Text] [Related]
8. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
9. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.
Wang J; Luo J; Jin K; Wang X; Yang Z; Ma J; Mei X; Wang X; Zhou Z; Yu X; Chen X; Guo X
Cancer Med; 2020 Apr; 9(7):2427-2434. PubMed ID: 32048817
[TBL] [Abstract][Full Text] [Related]
10. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Characteristics of
Lee MH; Cho JH; Kwon SY; Jung SJ; Lee JH
Int J Med Sci; 2020; 17(8):1131-1135. PubMed ID: 32410843
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
de Melo Gagliato D; Jardim DL; Falchook G; Tang C; Zinner R; Wheler JJ; Janku F; Subbiah V; Piha-Paul SA; Fu S; Hess K; Roy-Chowdhuri S; Moulder S; Gonzalez-Angulo AM; Meric-Bernstam F; Hong DS
Clin Breast Cancer; 2014 Dec; 14(6):468-74. PubMed ID: 25065564
[TBL] [Abstract][Full Text] [Related]
14. Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Edenfield J; Schammel C; Collins J; Schammel D; Edenfield WJ
Clin Breast Cancer; 2017 Feb; 17(1):e1-e10. PubMed ID: 27568101
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
16. Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub-analysis of the ProfiLER protocol.
Rowinski E; Magné N; Fayette J; Daguenet E; Racadot S; Pommier P; Méry B; Vallard A; Tinquaut F; Neidhardt-Berard EM; Cassier P; Attignon V; Pissaloux D; Wang Q; Sohier E; Pérol D; Blay JY; Trédan O
Head Neck; 2021 Dec; 43(12):3899-3910. PubMed ID: 34643313
[TBL] [Abstract][Full Text] [Related]
17. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
19. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]